Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Sermorelin

GHRH (1-29), GRF 1-29 NH2, Sermorelin acetate

Quick Stats
Studies 223
Trials 41
Score 4
1995 pubmed

Growth hormone-releasing hormone stimulates cAMP release in superfused rat pituitary cells.

Horváth. J E JE; Groot. K K; Schally. A V AV

Key Findings

  • GH release shows a dose‑dependent response to GHRH, with effective concentrations around 0.03 nM, while cAMP needs higher doses (≈0.3 nM) to be triggered.
  • cAMP release is not proportional to GH release; high GHRH doses keep raising cAMP but GH levels level off.
  • Repeated GHRH pulses cause quicker desensitization of GH release than of cAMP release.
  • Somatostatin blocks GH release induced by GHRH but does not prevent the immediate cAMP surge.

Practical Outcomes

  • For sermorelin users, short, spaced‑out pulses (e.g., a few minutes every few hours) may keep GH output higher and avoid rapid desensitization. Higher single doses might not boost GH further despite increasing cAMP, so modest dosing is likely sufficient. Avoiding simultaneous high somatostatin activity (e.g., fasting or certain nutrients that raise somatostatin) could help maintain GH spikes.

Summary

In rat pituitary cells, giving short bursts of growth‑hormone‑releasing hormone (GHRH) triggers both growth hormone (GH) and the messenger molecule cAMP, but the two don't rise together. Low GHRH doses barely raise cAMP, and even high doses make cAMP keep climbing while GH plateaus. Repeating GHRH pulses makes the cells lose their GH response faster than their cAMP response, and somatostatin can shut down GH release without stopping the immediate cAMP spike.

Abstract

The release of growth hormone (GH) and cAMP was studied in superfused rat pituitary cells by infusing growth hormone-releasing hormone (GHRH) at different doses or a combination of GHRH and somatostatin 14 (SS-14). Three-minute pulses of GHRH caused a dose-dependent GH and cAMP release (effective concentration of 50% of the maximal biological effect is 0.21 nM and 52.5 nM, respectively). The lowest effective doses of GHRH in the superfusion system were 0.03 nM for GH release and 0.3 nM for cAMP discharge when 3-min pulses were applied. The amount of cAMP liberated from the cells was not proportional to GH release: cAMP responses to low doses of GHRH were disproportionally small, and the gradual increase in the release of cAMP after high doses of GHRH was not followed by a parallel rise in GH release. The desensitization induced by repeated pulses or prolonged infusion of GHRH resulted in a greater reduction in GH release than in cAMP liberation. A simultaneous infusion of SS-14 completely blocked GH release stimulated by GHRH but did not inhibit the immediate release of cAMP caused by GHRH. An abrupt decrease in GHRH-stimulated GH release induced by SS-14 was followed by only a minimal reduction in cAMP liberation 9 min later. Our findings indicate that a discharge of cAMP is stimulated after a GHRH pulse, but this effect alone cannot maintain the release of GH. Other steps of the signal transduction mechanisms that are independent of the cAMP route may participate in the process of GH release. The nature of the mechanisms involved in the mediation of GH release may vary with the doses of GHRH used.

Study Information

Provider

pubmed

Year

1995

Date

1995-03-14T00:00:00.000Z

DOI

10.1073/pnas.92.6.1856